Frazier Life Sciences and Deep Track Capital led a $115m Series D funding in Maze Therapeutics.

Private equity companies Frazier Life Sciences and Deep Track Capital, led a $115m Series D funding in Maze Therapeutics, a clinical-stage biopharmaceutical company, with participation from Janus Henderson Investors, Logos Capital, Third Rock Ventures, ARCH Venture Partners, Matrix Capital Management, GV, General Catalyst, Andreessen Horowitz, Foresite Capital, Woodline Partners, Casdin Capital, Piper Heartland Healthcare Capital, Moore Strategic Ventures. “We are grateful and honored to have had the continued support of our long-term investors over the past several years and are thrilled to welcome the Frazier, Deep Track, Janus and Logos teams as we advance our two lead clinical programs, MZE829 and MZE782, and continue to leverage our Compass Platform. The additional resources provided by this financing will allow us to optimize our upcoming Phase 2 trial of MZE829 and further explore the potential of both lead programs. This financing marks an important step in our growth as a company, and for the patients we aim to serve,” Jason Coloma, Maze CEO.